Transthyretin-directed RNA Interaction Drug Class List

Drugs in Drug Class: Transthyretin-directed RNA Interaction

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes	9,370,581		Y	Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes	10,806,791			Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes	8,828,956		Y	Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes	10,131,907		Y	Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes

Transthyretin-Directed RNA Interaction Drugs: Market Dynamics and Patent Landscape (Exclusivity, Litigation, Generics Risk)

Last updated: June 22, 2026

What are transthyretin-directed RNA interaction drugs and how fast is the market growing?

Transthyretin-directed RNA interaction (TTR-RNAi) drugs are designed to lower circulating transthyretin (TTR) by reducing hepatic TTR production through antisense or RNA interference mechanisms. The commercial core is late-stage hereditary transthyretin amyloidosis (hATTR) with polyneuropathy, with expansion pathways tied to earlier disease stages, broader dosing regimens, and manufacturing scale.

Core products in the TTR-RNA interaction category

• Inotersen (Tegsedi): antisense oligonucleotide (ASO) delivered subcutaneously.
• Patisiran (Onpattro): siRNA lipid nanoparticle (LNP) delivered IV.
• Vutrisiran (Amvuttra): siRNA LNP delivered subcutaneously.
• Tafamidis and diflunisal are TTR stabilizers, not RNA-directed interactions; they compete for patient share but sit outside the mechanistic patent set for TTR-RNA interaction.

Market dynamics that affect patent and licensing outcomes

• Site of action drives differentiation. IV vs subcutaneous delivery can reduce administration friction, affecting payer adoption and switching behavior.
• Dose frequency reduces retention risk. Monthly or less frequent administration increases continuity, lowering substitution pressure ahead of patent expiry.
• Combination and line-of-therapy structure matters. RNA interaction agents are commonly used as long-term disease-modifying therapy. Changes in sequencing or eligibility can move addressable patient populations closer to older exclusivity cliffs.
• Manufacturing scale and drug-device constraints shape generic entry risk. For LNP siRNA, process IP and formulation/particle engineering often become the practical barrier set, even when composition-of-matter patents thin out.

Which companies hold the dominant patent estates for TTR-RNA interaction drugs?

The TTR-RNA interaction patent landscape centers on three incumbents tied to the key actives:

• Inotersen: Ionis Pharmaceuticals and Akcea Therapeutics (commercially via Tegsedi).
• Patisiran: Alnylam Pharmaceuticals (commercially via Onpattro).
• Vutrisiran: Alnylam Pharmaceuticals (commercially via Amvuttra).

The estates typically split into:

• Core sequence and chemistry patents (antisense/siRNA oligonucleotide sequences and chemical modifications).
• Delivery platform and LNP patents (for siRNA).
• Method-of-treatment and dosing regimen patents (patient populations, endpoints, and administration schedules).
• Manufacturing process and formulation patents (particle composition, buffer systems, conjugated lipids, and quality attributes).
• Regulatory exclusivity (5-year new chemical entity style exclusivity is not the same as patent term; it can extend practical market protection, especially for follow-on dosage forms).

What patents protect inotersen (Tegsedi) and how is exclusivity structured?

Inotersen is the antisense anchor for the TTR-RNA interaction class. Patent protection is usually layered as (1) oligonucleotide sequence and chemistry, (2) antisense binding/targeting methods, (3) pharmaceutical compositions and dosing, and (4) manufacturing/process claims.

Patent estate structure: typical layers for ASO

• Sequence/chemistry: chemical modifications (eg, backbone and sugar modifications) and nucleotide sequence claims.
• Target engagement: binding and mechanism claims tied to TTR mRNA.
• Formulation and administration: subcutaneous dosage form, stabilizers, and injection-ready composition.
• Methods of use: treatment of hATTR polyneuropathy or other TTR-mediated phenotypes, including stratified dosing.
• Manufacturing: synthesis methods, purification steps, and scale-up parameters.

Exclusivity and switching dynamics

Inotersen’s market dynamics are shaped by:

• Clinical adoption lag vs RNAi. In practice, siRNA agents often capture a larger share in payer formularies when administration is acceptable and clinical positioning is favorable.
• Subcutaneous vs patient logistics. Inotersen is subcutaneous, which improves retention versus IV-only agents, but siRNA subcutaneous (vutrisiran) competes on comfort and administration standardization.

Litigation and generic entry timing signals

For ASO, generic entry is not just a “sequence match.” Courts and regulators scrutinize chemical similarity, binding affinity, and functional equivalence. That makes formulation and chemistry patent layers more operational than composition-only cliffs.

What patents protect patisiran (Onpattro) and how do delivery-system patents affect generic risk?

Patisiran is a siRNA LNP product. The patent estate typically includes:

• siRNA sequence and design patents.
• LNP composition and structure claims (lipids, molar ratios, targeting ligands if used, and particle assembly).
• Manufacturing/process patents governing particle size distribution and encapsulation efficiency.
• Method-of-use patents for hATTR polyneuropathy and dosing regimen.

Delivery system IP is a gate for follow-on entry

Unlike small-molecule generics, for LNP siRNA:

• Process parameters determine critical quality attributes like particle size, polydispersity, encapsulation yield, and stability.
• Even if a competitor designs an alternate sequence, LNP and process IP can block “non-infringing but functionally similar” manufacturing.

Patent expiry and practical competition

In siRNA, the earliest “patent-thinning” often happens after:

• Sequence/chemistry patents end.
• Then delivery and process claims become the primary enforcement targets.
• Finally, method-of-use claims can delay label and clinical positioning even when drug substance is available.

What patents protect vutrisiran (Amvuttra) and how does subcutaneous administration change the competitive landscape?

Vutrisiran is Alnylam’s siRNA LNP variant designed for subcutaneous administration, which shifts the competitive plane versus patisiran and creates a distinct commercialization and IP map.

Estate components for vutrisiran

• siRNA design patents: sequence and siRNA chemistry.
• LNP composition: particle engineering supporting subcutaneous delivery and stability.
• Formulation: injection-ready composition, excipients, and storage stability specs.
• Dosing and methods of treatment: regimens and patient stratification for hATTR indications.

How subcutaneous dosing reshapes market dynamics

• Payer and site-of-care alignment. Subcutaneous administration reduces infusion-center utilization and can improve uptake.
• Switching friction. Patients already stabilized may remain on a current therapy, but switching can occur when payers prefer less resource-intensive administration.
• Generic substitution risk changes. A generic that only matches the drug substance may still face process and formulation blocks, making entry more time-consuming.

When does exclusivity end for TTR-RNA interaction drugs, and what are the “cliff points” for competition?

For high-stakes market planning, “exclusivity” should be treated as two layers:

1. Regulatory exclusivity (data exclusivity and new-indication exclusivity under FDA frameworks where applicable).
2. Patent term (including active and later expiring claims, patent term adjustments, and any patent term extensions).

Practical cliff points used in market forecasts

• Primary composition/sequence expiry: usually unlocks substance-level generic design.
• Delivery/formulation process expiry: determines whether a competitor can manufacture a compliant product.
• Method-of-use expiry: can delay the ability to freely position a generic on the same clinical indication.

Timeline mapping approach (how companies model it)

• Identify the last-to-expire claim in each estate category (sequence, LNP delivery, process, formulation, and method of use).
• Map that date to:
  • anticipated generic filing window (often aligned to Paragraph IV for patent-challenging strategies), and
  • potential settlement timing (carve-outs and brand/generic launch entry dates).

Which Paragraph IV challenges have been filed for TTR-RNA interaction patents?

This analysis requires verified Orange Book patent listings and specific Paragraph IV dockets. Without those listings and litigation docket records, it is not possible to produce a complete and accurate “filed vs pending vs settled” list for TTR-RNA interaction drugs in this response set.

What is the Orange Book status of inotersen, patisiran, and vutrisiran?

Orange Book status requires drug-specific patent listing extraction (including US patent numbers, listed expiration dates, dosage form, and whether patents are “drug substance” or “drug product”). Without verified listing extraction in this response, the correct Orange Book status cannot be stated.

How strong is the patent estate for TTR-RNA interaction drugs?

Patent strength is typically measured by:

• number of enforceable claims still in force,
• breadth of claims across chemistry, delivery, formulation, and methods of use, and
• litigation track record and outcomes.

Category-level strength pattern

• ASO (inotersen): strength tends to persist longer via chemistry and formulation patents and because functional equivalence hinges on chemical similarity.
• LNP siRNA (patisiran, vutrisiran): strength tends to persist via particle composition and manufacturing process claims, which are harder to “design around” without triggering infringement.

Competitive implication

Even after the earliest patents expire, generic entry risk remains elevated until:

• delivery-system IP thins substantially, and
• method-of-use claims are no longer blocking the exact indication and dosing regimen.

What generic entry risks exist for transthyretin RNA interaction products?

Generic entry risk for TTR-RNA interaction drugs is constrained by:

• Functional equivalence requirements for ASO and siRNA.
• Process and formulation IP for LNP delivery.
• Stability and quality attributes that are often treated as critical product features.
• Method-of-use limitations that can delay label parity.

Typical “design-around” avenues competitors pursue

• Alternate siRNA sequences or chemical modifications (while maintaining target knockdown).
• Different LNP composition or manufacturing processes that preserve particle attributes without copying claim elements.
• Different dosing regimens that avoid certain method-of-use claims.

Real-world blocker

For LNP siRNA in particular, particle engineering and manufacturing controls are tightly coupled to product performance. That increases the practical cost of equivalence and increases IP friction beyond basic composition-of-matter.

How do patent estates compare: inotersen vs patisiran vs vutrisiran?

A structured comparison for planning purposes should separate:

• core drug substance IP,
• delivery/platform IP,
• method-of-use IP,
• manufacturing/formulation IP,
• and expected “last-to-expire” claim categories.

Comparative positioning that affects R&D and licensing

• Inotersen: ASO chemistry and injection formulation tend to dominate remaining enforcement.
• Patisiran: LNP composition and manufacturing are key enforcement targets.
• Vutrisiran: subcutaneous LNP formulation and dosing method patents often drive the last phase of brand protection.

What patent litigation affects TTR-RNA interaction market access?

To identify litigation that affects market access, this response requires docket-verified case lists, including:

• case captions,
• asserted patents,
• filing dates,
• procedural posture (dismissed, settled, injunction),
• settlement terms that impact launch timing.

Those verified litigation details are not provided in the available input for this response.

Are licensing deals and settlements shaping the generics roadmap for these products?

Settlement terms and licenses are central to forecasting generic launch timing, but a correct deal map requires:

• verified settlement agreements,
• consent judgments,
• court-filed terms tied to specific patents and dates.

Those details are not available in this response set.

How do FDA regulatory pathways interact with patent strategy for TTR-RNA interaction drugs?

For RNA interaction products, regulatory pathways influence when a challenger can rely on prior data and how quickly label parity can be achieved. Strategy typically aligns with:

• the ability to file an abbreviated application or demonstrate sameness,
• the time needed to validate functional equivalence,
• and whether method-of-use or dosing claims block label entry even after patent term for substance expires.

Commercial timing impact

• A challenger may be able to manufacture and demonstrate equivalence before final label parity.
• Brand exclusivity and method-of-use patents can delay meaningful substitution even if substance patents expire earlier.

Key Takeaways

• TTR-RNA interaction drugs are dominated by inotersen (Ionis/Akcea) and Alnylam’s siRNA LNP products (patisiran, vutrisiran).
• Patent protection is layered across drug substance, delivery system, formulation/manufacturing, and method-of-use. For siRNA LNP, delivery and manufacturing/process IP typically drives generic entry friction beyond sequence-level design.
• Market entry forecasting depends on mapping last-to-expire claim categories rather than the earliest composition-expiry date.
• Accurate assessment of Paragraph IV challenges, Orange Book status, and litigation/settlement launch effects requires drug-specific Orange Book listing extraction and docket-level case mapping, which are not included in the current response inputs.

FAQs

1. What delivery-system patents usually block generic competition for LNP siRNA drugs in the transthyretin field?
2. How do method-of-use patents delay label parity even when drug substance patents expire first?
3. What manufacturing quality attributes matter most for functional equivalence in siRNA LNP products?
4. How does subcutaneous administration influence payer adoption and switching behavior between patisiran and vutrisiran?
5. What is the typical sequence of patent expiry categories that brand teams monitor for hATTR RNA interaction products?

References

1. (No citations provided in the input data for this response.)